The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

Authors:

Abstract
PsA is a chronic inflammatory arthropathy affecting up to 40% of patients with skin or nail psoriasis. It is considered a type of seronegative spondyloarthritis and can cause arthritis, enthesitis, dactylitis and axial inflammation. The use of anti-TNF therapy for the treatment of inflammatory arthritis, including PsA, has revolutionized therapeutic options in rheumatology.

This publication has 2 references indexed in Scilit: